Keywords
Morbidity
Quality life
Healthcare
Expert opinion
Long-term prophylaxis
C1 inhibitor
Lanadelumab
Berotralstat
México
How to Cite
Abstract
BACKGROUND: Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent, bradykinin-mediated swelling episodes, with substantial impact on morbidity, quality of life, and healthcare resource use. Targeted agents have reshaped long-term prophylaxis (LTP); however, effective implementation depends on clinical decision-making as well as health-system access and structural constraints.
OBJECTIVE: To comprehensively describe HAE long-term prophylaxis management in Mexico, focusing on the diagnostic approach, LTP use, treatment access and availability, perceived disease control, and applicability of clinical recommendations, based on structured national expert opinion.
METHODS: We conducted a descriptive and analytical evaluation of Mexico-specific data derived from a structured Delphi process involving clinicians experienced in HAE management. Assessed domains included diagnostic testing practices, selection and prescribing frequency of LTP therapies, use of non-recommended treatments, funding sources, medication availability issues, access barriers, and clinicians’ perceptions regarding disease control and guideline applicability.
RESULTS: Experts reported strong conceptual alignment with current clinical recommendations. LTP prescribing was predominantly concentrated on lanadelumab, with limited use of C1-INH concentrates and no reported use of berotralstat. Despite reported public coverage, frequent barriers related to availability and cost constrained effective access and treatment continuity. Clinical guidelines were perceived as highly applicable; however, a gap between recommended care and feasible real-world implementation was consistently acknowledged.
CONCLUSIONS: HAE prophylaxis management in Mexico appears aligned with contemporary standards, yet sustained and individualized implementation remains limited by structural access and supply constraints. Key priorities include strengthening timely diagnosis, ensuring continuous access to targeted therapies, and standardizing follow-up in routine clinical care.
KEYWORDS: Hereditary angioedema; Morbidity; Quality life; Healthcare; Expert opinion; Long-term prophylaxis; C1 inhibitor; Lanadelumab; Berotralstat; Mexico.
References
1. Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med 2020; 382: 1136-1148. doi:10.1056/NEJMra1808012
2. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—2021 revision and update. Allergy 2022; 77: 1961-1990. doi:10.1111/all.15214
3. Kaplan AP, Joseph K. Pathogenesis of hereditary angioedema: the role of the bradykinin-forming cascade. Immunol Allergy Clin North Am 2017; 37:513-525. doi: 10.1016/j.iac.2017.04.001
4. Wilkerson RG, Moellman JJ. Hereditary angioedema. Immunol Allergy Clin North Am 2023; 43: 533-552. doi: 10.1016/j.iac.2022.10.012
5. Li HH. Hereditary angioedema: long-term prophylactic treatment. Allergy Asthma Proc 2020; 41 (Suppl 1): S35-S37. doi:10.2500/aap.2020.41.200092
6. Longhurst HJ, Valerieva A. A review of randomized controlled trials of hereditary angioedema long-term prophylaxis with C1 inhibitor replacement therapy. J Asthma Allergy 2023; 16: 269-277. doi:10.2147/JAA.S396338
7. Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy 2012; 67: 1289-1298. doi:10.1111/all.12007
8. Chong-Neto HJ. Quality of life in hereditary angioedema patients: a narrative review. World Allergy Organ J 2023; 16: 100758. doi: 10.1016/j.waojou.2023.100758
9. Nieto S, Madrigal I, Contreras F, Vargas ME. Real-world experience of hereditary angioedema in Mexico. World Allergy Organ J 2023; 16: 100812. doi: 10.1016/j.waojou.2023.100812
10. Vargas-Camaño ME, Buendía-López YO, Garcés-Flores H, Guzmán-Vázquez S. Hereditary angioedema: patient journey approach in Mexico. Rev Alerg Mex 2023; 70: 121-128. doi:10.29262/ram. v70i3.1250
11. Yong PFK, Annals R, Diwakar L, et al. Prophylaxis in hereditary angioedema: a United Kingdom Delphi consensus. Clin Exp Immunol 2024; 217: 109-116. doi:10.1093/cei/uxae020
12. Martinez-Saguer I, Dominas N, Straben U, et al. Patients with hereditary angioedema and their treatment patterns in Germany: a Delphi consensus study. Eur J Dermatol 2022; 32: 487-494. doi:10.1684/ejd.2022.4272
13. Tachdjian R, Johnson KE, Casso D, et al. Real-world cohort study of adult and pediatric patients treated for hereditary angioedema in the United States. Allergy Asthma Proc 2020; 41: 172-182. doi:10.2500/aap.2020.41.200011
14. Riedl MA, Banerji A, Manning ME, et al. Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States. Orphanet J Rare Dis 2018; 13: 180. doi:10.1186/s13023-018-0922-3
15. Riedl MA, Hinds DR, Prince PM, et al. Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate. Allergy Asthma Proc 2023; 44: 275-282. doi:10.2500/aap.2023.44.230026
16. Princic N, Evans KA, ShAEH CH, et al. Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis. J Comp Eff Res 2025; 14: e240205. doi:10.57264/cer-2024-0205
17. Aberer W, Altrichter S, Cerpes U, et al. Hereditary angioedema due to C1-inhibitor deficiency: a national disease management programme. Wien Klin Wochenschr 2023;135 (Suppl 8):785-798. doi:10.1007/s00508-023-02298-x
18. Zuraw BL, Lopez-Gonzalez L, Manjelievskaia J, et al. Adherence and persistence among patients with hereditary angioedema receiving long-term prophylaxis in the United States. Allergy Asthma Proc 2025; 46: 209-217. doi:10.2500/aap.2025.46.250029
19. Donadoni M, La Cava L, Bizzi E, et al. Hereditary angioedema prophylaxis therapy: berotralstat and lanadelumab safety profile. Medicina (Kaunas) 2025; 61: 1897. doi:10.3390/medicina61111897
20. Walsh S, Bartlett M, Salvo-Halloran EM, et al. Network meta-analysis of pharmacological therapies for long-term prophylactic treatment of patients with hereditary angioedema. Drugs R D 2025; 25: 161-178. doi:10.1007/s40268-025-00511-y
21. Beard N, Frese M, Smertina E, et al. Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev 2022; 11: CD013403. doi: 10.1002/14651858.CD013403.pub2
22. WAEHn V, Aberer W, Aygören-Pürsün E, et al. Hereditary angioedema in children and adolescents: a consensus update on therapeutic strategies. Pediatr Allergy Immunol 2020; 31: 974-989. doi:10.1111/pai.13309
23. WAEHn V, Aberer W, Eberl W, et al. Hereditary angioedema in children and adolescents: a consensus on therapeutic strategies. Eur J Pediatr 2012; 171: 1339-1348. doi:10.1007/s00431-012-1726-4
24. Frank MM, Zuraw B, Banerji A, et al. Management of children with hereditary angioedema due to C1 inhibitor deficiency. Pediatrics 2016; 138: e20160575. doi:10.1542/peds.2016-0575
25. Lumry WR. Hereditary angioedema: the economics of treatment of an orphan disease. Front Med (Lausanne) 2018; 5: 22. doi:10.3389/fmed.2018.00022
26. Bernstein JA. Severity of hereditary angioedema, prevalence, and diagnostic considerations. I am J Manag Care 2018; 24 (Suppl 14): S292-S298.
27. Bellanti JA, Settipane RA. From burden to breakthrough: Advances in hereditary angioedema, drug allergy, and allergic disease prevention. Allergy Asthma Proc 2025; 46 (3): 161-164. doi:10.2500/aap.2025.46.250030
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2026 Revista Alergia México